GlassScriptPhysician profile
Karyn Tetloff
NPI 1487156808
$3,691.05
in general payments reported to CMS, 2019-2025
43 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.82 · 2022: $84.53 · 2023: $502 · 2024: $1,211 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $297.82 | 2023-2025 | Fintepla, Rystiggo, Nayzilam |
| Abbvie INC. | $199.79 | 2023-2025 | |
| Biogen, INC. | $197.12 | 2023-2025 | Tysabri, Skyclarys, Vumerity |
| Argenx US, INC. | $193.48 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $191.01 | 2023-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $184.51 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $173.23 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $163.38 | 2023-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $155.32 | 2024-2025 | Hyqvia |
| Eisai INC. | $148.32 | 2024-2025 | |
| Depuy Synthes Sales INC. | $120.79 | 2024 | Cerebase |
| Imperative Care, INC | $120.48 | 2023 | Zoom 88-T Large Distal Platform |
| Aucta Pharmaceuticals, INC. | $115.13 | 2024-2025 | Motpoly Xr |
| Pfizer INC. | $113.94 | 2024-2025 | |
| Microvention, INC. | $107.59 | 2024 | Stent, Tubing Kit - Stroke, Eric Retrieval Device |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $107.16 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $90.66 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $89.09 | 2023-2025 | Fycompa |
| Vanda Pharmaceuticals INC. | $81.91 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $81.60 | 2024-2025 | Radicava |
| Acadia Pharmaceuticals INC | $66.42 | 2023-2025 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $64.36 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Hospira, INC. | $57.92 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $55.45 | 2025 | Onpattro |
| Otter Pharmaceuticals, LLC | $49.62 | 2025 | Sympazan |
| Acorda Therapeutics, INC | $48.55 | 2023 | Inbrija |
| Lilly USA, LLC | $45.66 | 2023-2025 | Amyvid, Kisunla |
| Microtransponder, INC. | $39.65 | 2025 | |
| Kyowa Kirin, INC. | $34.49 | 2021 | |
| Cala Health, INC. | $33.43 | 2022-2024 | Cala Kiq, Cala Trio |
| Lundbeck LLC | $29.12 | 2025 | Vyepti |
| Tg Therapeutics, INC. | $27.39 | 2025 | |
| Upsher-Smith Laboratories LLC | $26.54 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.81 | 2025 | Keveyis |
| Celgene Corporation | $24.05 | 2024 | Zeposia |
| Itf Therapeutics LLC | $19.51 | 2025 | |
| Avion Pharmaceuticals | $18.51 | 2022 | |
| Greenwich Biosciences, INC. | $17.33 | 2021 | |
| Averitas Pharma INC. | $16.58 | 2025 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.39 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $15.76 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $15.23 | 2023 | Aptiom |
| Allergan, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Tetloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.